1-3 LPD after allogeneic bone marrow transplant (BMT) runs a more aggressive course than that after organ transplantation. Cord blood (CB) is an alternative stem cell source containing early committed progenitor cells and immature lymphocytes. 4, 5 Recent reports of transplants with related and/or unrelated partially HLA-mismatched CB have shown comparable engraftment with a small dose of nucleated cells (ෂ4 × 10 7 /kg), and a lower incidence of graft-versus-host disease (GVHD) than expected with BM grafts.
Lymphoproliferative disease (LPD) is a serious complication of immunocompromised hosts, that usually derives from the proliferation of Epstein-Barr virus (EBV)-infected B cells. [1] [2] [3] LPD after allogeneic bone marrow transplant (BMT) runs a more aggressive course than that after organ transplantation. Cord blood (CB) is an alternative stem cell source containing early committed progenitor cells and immature lymphocytes. 4, 5 Recent reports of transplants with related and/or unrelated partially HLA-mismatched CB have shown comparable engraftment with a small dose of nucleated cells (ෂ4 × 10 7 /kg), and a lower incidence of graft-versus-host disease (GVHD) than expected with BM grafts. [5] [6] [7] CB transplant (CBT) may carry a low risk of EBV or cytomegalovirus (CMV)-associated complications because CB carries no herpes viruses. Despite the rapid increase in the number of CBT, post-transplant LPD has Correspondence: Dr S Ohga, Department of Pediatrics, Graduate School of Medicine Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan Received 28 April 1999; accepted 23 September 1999 never been reported. To date, at least five successful CBT have been performed for DBA, [8] [9] [10] [11] [12] although the indications for bone marrow (BM) failure syndromes are still controversial.
We describe a patient with Diamond-Blackfan anemia (DBA) who developed donor derived EBV-LPD following complete engraftment of unrelated CB. The complications of CBT are discussed and the potential indications for stem cell transplants in DBA patients are discussed.
Materials and methods

Dot blotting and Southern blotting of the EBV genome
High molecular DNA was extracted from peripheral blood, pleural effusion, BM cells, liver, spleen and lymph nodes. Dot blotting to detect the EBV-DNA was performed based on the PCR protocol, using the EBV primer specific for a 240-basepair (bp) region within the BamHI-K region containing the internal repeated (IR) sequences of the EBV genome. 13 Southern blotting probed with EBV-terminal repeat (TR) genes was performed as previously described. 13 Clonal analysis using the PCR method PCR protocol was used for amplification of the immunoglobulin heavy (IgH) chain gene using the Fr3A V-region primer (5′-ACA/CGG/C[C/T][G/C]/TGT/ATT/ACT/GT-3′) in conjunction with the nested primer directed to the J region (VLJH: 5′-GTG/ACC/AGG/GTN/CCT/TGG/ CCC/CAG-3′).
14 Clonality was assessed by the amplified PCR products, which represented the diversity of the complementarity determining region (CDR) 3 genes of IgH. Control DNA was obtained from a cell line of B cell lymphoma or peripheral blood of a healthy adult.
Histopathological examinations
Necropsy specimens were immunohistochemically stained with anti-CD3, CD20, CD79a, Ber-H2, MPO, UCHL-1, LMP, PE2 antibodies (Abs) (Ortho, Raritan, NJ, USA; Dako, Glostrup, Denmark; Novocastra, Newcastle upon Tyne, UK). 15 In situ hybridization (ISH) using EBE-1 antisense oligonucleotide was carried out to find EBV-encoded RNA 1 (EBER-1)-expressing lymphocytes. 15 
Short tandem repeat (STR) polymorphism
The STR typing was performed to determine the origin of tumor cells according to the previous method. 16 The polymorphic patterns using the primers for TPOX, vWA, D16S539, D7S820, D13S317, D5S818 were compared between DNA obtained from lymphoma tissue, pretransplant BM cells (recipient type) and post-transplant BM cells engrafted completely (donor type).
Case report and results
A 7-year-old Japanese boy was admitted to our hospital for an unrelated CBT. He was a child of non-consanguineous parents without a family history of hematologic disease. He was born to a mother who had taken no medication and who had had no infections during the pregnancy at 37 weeks of gestation. He weighed 2450 g at birth. DBA was dignosed on the findings of anemia, ear deformity, webbed neck, dysmorphic facies, and bicuspid aortic valves. Cytogenetic studies showed a normal karyotype of 46,XX. There was no immunodeficiency. Prednisolone (PSL), cyclosporin A (CsA), cyclophosphamide (CY), danazol and erythropoietin were ineffective for treatment of the anemia. Hemochromatosis progressed with liver dysfunction, cardiomegaly and glucose intolerance. No donor was identified on the Japan Marrow Donor Program.
On admission, physical examination revealed a pale boy with the above abnormalities. Respiratory sounds were normal and a systolic heart murmur was present. The liver was palpable 2 cm below the costal margin, and the spleen was not palpable. There was no lymphadenopathy. Peripheral blood counts showed: WBC 5.50 × 10 9 /l with 44% segmented neutrophils, 48% lymphocytes, 2% eosinophils, and 7% monocytes, RBC 1470 × 10 ance test indicated borderline diabetes mellitus. Serological examination revealed a past infection with EBV, but no CMV, hepatitis A, B or C viruses, or human T lymphotropic virus I. BM study revealed a few erythroid (M/E ratio: 8.9) without abnormal blasts. Chest X-ray showed 60% marked cardiomegaly. Echocardiogram revealed bicuspid valves and a hypertrophic left ventricle. Magnetic resonance imaging (MRI) indicated iron deposition in the liver, spleen and pancreas. The total amount of red cell transfusions had reached 68 400 ml.
An unrelated female UCB (blood type: A, Rh+) from a Japanese CB bank was used for the recipient (blood type: O, Rh+). High resolution HLA-typing showed a one locusmismatched phenotype and 3 locus-mismatched genotype (Table 1) . CsA and PSL were administered for GVHD prophylaxis. The WBC count exceeded 1000/l on day 26. Reticulocytes increased to 2% on day 39. Red cell transfusion was stopped on day 33, but platelets were transfused weekly until day 100. On day 33, chromosomal analysis using fluorescence in situ hybridization (FISH) showed 46, XX in 200 BM cells examined. Complete engraftment has been continuous until day 122. CsA encephalopathy occurred on day 23. Transaminase levels peaked on day 30 (AST 607 U/l, ALT 1509 U/l). Skin GVHD (grade II) appeared on day 65, which responded to oral PSL therapy.
On day 107 of transplant, the skin eruption recurred. Fever and cervical adenopathy appeared on day 118 after transplant, followed by cytopenia and liver dysfunction. There was no evidence of infections. The patient died of hepatic failure and pulmonary infiltrates on day 130 post transplant. EBV-DNA was detected in peripheral blood and pleural effusion. Southern blot analysis indicated monoclonal EBV proliferation (Figure 1 ). Analysis of IgH CDR3 region genes using PCR products amplified with the Fr3A primer suggested clonal expansion of B cells in spleen, liver, lymph node, and effusions ( Figure 2 ). Necropsy demonstrated diffuse large cell lymphoma infiltrating liver, spleen and lymph node. The atypical cells were positive for CD20, CD79a, and focal EBV-LMP, EBV (PE2), Ber-H2, but negative for MPO, UCHL-1 and CD3. The frequency of EBER1-expressing lymphocytes was increased in liver or spleen. STR typing revealed that the tumor was of donor origin (data not shown). Retrospective quantification of EBV-DNA using the quantitative PCR methods reflected the development of LPD (4 × 10 5 copies/ml).
Discussion
This is the first report of EBV-LPD following CBT. Posttransplant LPD can develop after allogeneic 17, 18 or autolog- The related donors were all HLA-matched siblings. Unrel = unrelated; Sib = sibling; TBI = total body irradiation; TAI = thoracoabdominal irradiation; CY = cyclophosphamide; BU = busulfan; ATG/ALG = anti-thymocyte/lymphocyte globulin; CsA = cyclosporin A; mPSL = methylprednisolone; MTX = methotrexate; GVHD = graft-versus-host disease.
Bone Marrow Transplantation ous 3 BMT. It arises generally from donor B cells after allogeneic BMT, but from recipient B cells after autologous BMT or organ transplants. T/NK cell-derived LPD is extremely rare. 13, 15, 19 LPD is difficult to diagnose because of the low incidence and extranodal pattern of involvement. A third of cases are confirmed post mortem. 18 In the present case, necropsy verified diffuse large cell lymphoma and confirmed the clonal proliferation of EBV-infected B cells of donor origin. The most salient point was the portal of entry of the virus. The recipient was seropositive for EBV pretransplant. The donor was confirmed to be healthy at 6 months of age. EBV genome was not detected in the donor CB (data not shown). Thus, the primary EBV infection must have passed into the engrafted donor cells from residual host cells, or via the frequent blood transfusions. Gross et al 18 indicated that T cell depletion, HLA-mismatching, donor age, and underlying immunodeficiency were risk factors for B cell LPD following BMT. No association has been suggested between DBA and congenital immunodeficiency diseases. ATG conditioning, skin GVHD, and advanced hemochromatosis might have influenced T cell immunity against EBV infection in our patient. The viral load retrospectively accounted for the development of LPD. Donor lymphocyte infusion is one of the encouraging treatments for post-transplant LPD, however, it is impossible in CBT. Sequential monitoring of viral DNA is needed for identifying reactivation and early diagnosis of associated complications in this type of transplant.
DBA is characterised by an intrinsic defect in erythroid precursors. 20 Approximately 30% of patients become steroid and/or transfusion dependent. Since the first successful BMT published in 1976, 21 more than 31 BMT for DBA have been reported and 10 patients have died of rejection, GVHD and/or infections. [21] [22] [23] To date, six CBT from HLAmatched siblings [8] [9] [10] [11] [12] and at least five unrelated CBT for DBA, 4, 24, 25 have been published. Of these cases, information from four related or one unrelated CBT are summarized in Table 2 . [8] [9] [10] [11] [12] 24, 25 All CB grafts have been successful except for our case, while the absolute cure rate for DBA by BMT is 63%. 23 Of the recipients with CBT, [8] [9] [10] [11] [12] 24, 25 our patient was the oldest with advanced hemochromatosis. Gluckman et al 12 reported that patients less than 6 years of age and weighing less than 20 kg demonstrated a favorable recovery of neutrophils after CBT. Despite poor conditions, myeloid and erythroid reconstitution was satisfactory in our patient. Cairo and Wagner 6 disclosed that four of five patients who failed to engraft had undergone CBT for the treatment of BM failure syndromes. A recent analysis of 562 cases of unrelated CBT 24 revealed that successful engraftment was reduced among patients with Fanconi anemia, severe aplastic anemia, and chronic myelogenous leukemia. However, numbers are too small to evaluate the outcome of DBA patients who have undergone CBT. Our observation emphasises the possibility of LPD after CBT. However, further studies are required to determine the feasibility of unrelated CBT for DBA.
